Abstract
The p53 tumor suppressor is a stress sensor, driving cell cycle arrest or apoptosis in response to DNA damage or oncogenic signals. p53 activation by oncogenic signals relies on the p19Arf tumor suppressor, while p53 activation downstream of acute DNA damage is reported to be p19Arf-independent. Accordingly, p19Arf-deficient mouse embryo fibroblasts (MEFs) arrest in response to acute DNA damage. However, p19Arf is required for replicative senescence, a condition associated with an activated DNA damage response, as p19Arf−/− MEFs do not senesce after serial passage. A possible explanation for these seemingly disparate roles for p19Arf is that acute and chronic DNA damage responses are mechanistically distinct. Replicative senescence may result from chronic, low-dose DNA damage responses in which p19Arf has a specific role. We therefore examined the role of p19Arf in cellular responses to chronic, low-dose DNA-damaging agent treatment by maintaining MEFs in low oxygen and administering 0.5 G y γ-irradiation daily or 150 μM hydroxyurea, a replication stress inducer. In contrast to their response to acute DNA damage, p19Arf−/− MEFs exposed to chronic DNA damage do not senesce, revealing a selective role for p19Arf in senescence upon low-level, chronic DNA damage. We show further that p53 pathway activation in p19Arf−/− MEFs exposed to chronic DNA damage is attenuated relative to wild-type MEFs, suggesting a role for p19Arf in fine-tuning p53 activity. However, combined Nutlin3a and chronic DNA-damaging agent treatment is insufficient to promote senescence in p19Arf−/− MEFs, suggesting that the role of p19Arf in the chronic DNA damage response may be partially p53-independent. These data suggest the importance of p19Arf for the cellular response to the low-level DNA damage incurred in culture or upon oncogene expression, providing new insight into how p19Arf serves as a tumor suppressor. Moreover, our study helps reconcile reports suggesting crucial roles for both p19Arf and DNA damage-signaling pathways in tumor suppression.
Similar content being viewed by others
Introduction
It has long been appreciated that mammalian cells undergo a permanent growth arrest response, termed cellular senescence, upon continued propagation in culture. In addition, cells can be driven to undergo an accelerated senescence response upon expression of select oncogenes. Both of these responses provide safeguard mechanisms against neoplasia, by blocking proliferation either in suboptimal growth conditions or in response to inappropriate proliferative signals. The importance of senescence in tumor suppression is underscored by the fact that both senescence responses are critically dependent on the p53 tumor suppressor, as well as its positive regulator, the Arf tumor suppressor, which acts to stabilize p53 through sequestration of the Mdm-2 ubiquitin ligase. Both p19Arf- and p53-deficient mouse fibroblasts are immortal, failing to undergo senescence upon passaging in culture or in response to expression of oncogenes such as activated Ras.1
Although one of the major cues that signals senescence with increasing passage of human cells is the attrition of telomeres, senescence-activating signals in mouse cells, which typically have long telomeres >20 kb, have remained less clear.2, 3 Senescence in mouse fibroblast cells has been correlated with high oxygen tension, as maintenance of cultures in low oxygen inhibits activation of the senescence program, either with increasing passage or with expression of oncogenes such as activated Ras.4, 5, 6, 7 Oxidative stress in fact not only contributes to senescence in mouse cells but also in human cells, as treatment of activated Ras-expressing human fibroblasts with scavengers of reactive oxygen species, such as N-acetyl cysteine, inhibits senescence,6 implicating reactive oxygen species in the senescence response. As one of the major consequences of reactive oxygen species accumulation is the induction of DNA strand breaks, the senescence induced under high oxygen tension is likely at least partially triggered by DNA damage.7, 8 This notion has been supported by the observation that oncogene-induced senescence relies on components of the DNA damage-signaling cascade, including Atm and Chk2.9, 10, 11
Although the idea that a DNA damage signal induces senescence is consistent with the known requirement of p53, a sensor of DNA damage, this model does not account for the participation of p19Arf, which has been reported to be dispensable for the response of cells to DNA damage.1, 12, 13, 14, 15 One possible explanation for this discrepancy is that the studies examining the role of p19Arf and p53 in the DNA damage response have typically been done in vitro through exposure of cells to a single, high dose of a particular genotoxin (such as 5–20 Gy γ-irradiation), which elicits a rapid cellular response, typically within 24 h.16, 17, 18 In contrast, the DNA damage driving senescence in cultured cells is chronic, low-level damage. Likewise, the DNA damage encountered during tumor development is not due to a single, acute genotoxic insult but rather continual, low-level genomic damage caused by unscheduled DNA replication and consequent replication fork collapse, telomere attrition, and increased reactive oxygen species levels resulting from enhanced metabolic activity or hypoxia/reperfusion.6, 19, 20, 21, 22, 23, 24 Thus, examining the mechanisms underlying responses to lower levels of chronic DNA damage, rather than a high acute dose, will likely provide a more accurate picture of how p53 acts to suppress cancer in vivo.
Here, we leverage a widely utilized mouse embryonic fibroblast (MEF) model system to examine the roles of p53 and p19Arf in the cellular responses to acute high-dose and chronic low-dose DNA damage. To allow controlled exposure to exogenous DNA damage, we grow cells in low-oxygen conditions to mitigate the effects of culture shock. Interestingly, we find that while both wild-type and p19Arf−/− fibroblasts undergo cell cycle arrest upon exposure to a single high dose of a DNA-damaging agent, wild-type cells also undergo cell cycle arrest upon chronic treatment with a low-dose DNA-damaging agent, but p19Arf−/− fibroblasts fail to do so. These findings suggest that p19Arf is critical for the response to the low-level DNA damage incurred under culture conditions or upon oncogene expression and provide new insight into replicative senescence. Importantly, our findings also help reconcile the contradiction that various genetic studies have shown that the response of p53 to acute DNA damage is dispensable for tumor suppression, while other studies have shown that DNA damage signals are observed in early tumors and suggested that these signals are important for p53-mediated tumor suppression.20, 21, 25, 26 Our observations suggest a mechanistic difference in the p53-dependent pathways leading to senescence/tumor suppression in response to acute and chronic DNA damage signals, in terms of the contribution of p19Arf. Our findings thus refine our understanding of p53-mediated tumor suppression by indicating that while p53’s ability to respond acute DNA damage is dispensable for tumor suppression, its ability to drive responses to chronic DNA damage may be crucial, providing significant new insight into both senescence and tumor suppression.
Results and discussion
Establishing assays for acute and chronic DNA damage responses
To study the cellular response to chronic, low-dose DNA damage, it was first necessary to develop assays for chronic and acute DNA damage responses. We defined an acute DNA-damaging agent as one where a single, high-dose treatment triggers rapid cell cycle arrest and a low-dose DNA-damaging agent as one where a single treatment fails to cause a proliferative arrest. Treatment with the DNA double-strand break inducer doxorubicin or 12 Gy γ-irradiation allows examination of acute DNA damage responses, as wild-type MEFs respond to these treatments by undergoing proliferative arrest 24 h after treatment (Figure 1a). In contrast, exposure to 0.5 Gy γ-irradiation, or to 150 μM hydroxyurea (HU)—a ribonucleotide reductase inhibitor and inducer of replication stress, a type of stress encountered by developing cancer cells11, 27—does not induce cell cycle arrest, as BrdU incorporation is similar to untreated cells 24 h after treatment (Figure 1a). To correlate arrest responses with p53 activity, we assessed p53 stabilization and transcriptional activity under these conditions. Although doxorubicin induced robust p53 protein stabilization after 8 h, 12 Gy γ-irradiation produced more modest p53 stabilization (Figure 1b). Both treatments, however, induced expression of the p53 target genes p21 and Mdm2 2 h after treatment (Figure 1c). In contrast, 0.5 Gy γ-irradiation or 150 μM HU did not induce significant p53 target gene expression (Figure 1c). Thus, activation of cell cycle arrest in wild-type MEFs correlates strongly with transactivation of target genes.
Although acute DNA damage treatment has been a useful tool to study the mechanisms of p53 activity in cell cycle arrest and senescence, the response to chronic, low-level DNA damage may represent a more accurate model for how p53 is induced in incipient tumor cells in vivo. Simply culturing primary MEFs ex vivo triggers a DNA damage response and replicative senescence after several passages, which is thought to result from oxidative stress that accumulates in the presence of 20% atmospheric oxygen. Accordingly, primary MEFs cultured in physiological oxygen levels (2–5%) do not activate a DNA damage response or undergo replicative senescence.7, 8 To ensure that the responses we measured were the result of the specified treatments and not damage triggered by growth at high oxygen tension and because the differences between culturing cells at atmospheric and physiological oxygen levels has not been analyzed systematically, we examined the cell cycle arrest responses to treatment with acute or low-dose DNA-damaging agents in cells cultured in 2% oxygen. Similarly to standard culture conditions, wild-type MEFs maintained in 2% oxygen and treated with 0.2 μg/ml doxorubicin or 12 Gy γ-irradiation underwent cell cycle arrest 24 h after treatment and displayed p21 and Mdm2 induction 2 h post treatment, while treatment with the lower dose of 0.5 Gy γ-irradiation or with 150 μM HU did not trigger cell cycle arrest or target gene induction (Figures 1d and f). Cells maintained in 2% oxygen also displayed p53 protein levels similar to cells at 20% oxygen after the various treatments, with a slight attenuation of p53 accumulation after doxorubicin treatment (Figure 1e). Analysis of Histone H2AX phosphorylation (γH2AX), a marker of DNA double-strand breaks, verified that DNA damage is present after both the acute and low-dose treatments, as numerous γH2AX foci were observed by immunofluorescence in wild-type MEFs 30 min after treatment with 0.2 μg/ml doxorubicin or 12 or 0.5 Gy γ-irradiation (Figure 1g).28, 29 These experiments thus establish a novel model system in which to study the chronic, low-dose DNA damage response in MEFs.
p19Arf is dispensable for the response to acute DNA damage
To elaborate the role of p19Arf in the DNA damage response, we first compared the responses of wild-type, p53-null and p19Arf-null MEFs maintained in 2% oxygen to acute DNA damage (Figure 2a). 24 h after treatment with 0.2 μg/ml doxorubicin or 12 Gy γ-irradiation, wild-type MEFs underwent a clear proliferative arrest and ultimately senesced, as assessed by expression of senescence-associated β-galactosidase (SA-β-gal) 10 days post treatment (Figure 2b). As expected, p53-null MEFs were unable to mount a response to acute DNA damage, and showed only a mild decrease in proliferation following doxorubicin treatment. In contrast, MEFs deficient for p19Arf, but retaining wild-type p53, underwent a proliferative arrest 24 h after doxorubicin or 12 Gy γ-irradiation treatment, followed by senescence 10 days later (Figure 2b). These data suggest that p19Arf is dispensable for acute DNA damage responses.18
p19Arf is required for the response to chronic, low-dose DNA damage
We next assessed whether p19Arf might contribute to the cellular response to chronic, low-dose DNA-damaging agent treatment. Toward this end, we grew wild-type MEFs in 2% oxygen, treated them daily with 0.5 Gy γ-irradiation and measured proliferation at several time points (Figure 2c). After 10 days of treatment, wild-type MEFs underwent a complete cell cycle arrest accompanied by SA-β-gal positivity (Figure 2d). Importantly, untreated wild-type MEFs maintained in 2% oxygen showed only a slight reduction in proliferation over the 10-day time course (Figure 2e), indicating that the senescence response in treated wild-type MEFs is due to daily 0.5 Gy γ-irradiation and not simply the result of any residual culture shock in a 2% oxygen environment. In contrast to wild-type MEFs, p53-null cells showed no evidence for cell cycle arrest or senescence after 10 days of daily γ-irradiation. Interestingly, in response to chronic, low-dose irradiation, p19Arf-deficient MEFs behaved similarly to p53-null cells, and neither mounted a cell cycle arrest response nor displayed senescence marker positivity after 10 days of daily 0.5 Gy γ-irradiation (Figure 2d). These findings indicate that p19Arf is critical for the cell cycle arrest response to chronic, low-dose DNA damage.
To generalize our results using a mimic of the physiological stress of replication fork collapse, we extended our analysis to HU. Prolonged exposure to HU has been shown to promote cell cycle arrest,30 and indeed, wild-type MEFs exposed to 150 μM HU exhibited a significant reduction in BrdU incorporation after 7 days and senescence after 10 days (Figure 2f). In the same time period, p53-null cells did not mount a significant cell cycle arrest response. Similarly, the ability of p19Arf-deficient MEFs to undergo cell cycle arrest and senescence in response to chronic HU treatment was largely compromised (Figure 2f), confirming a role for p19Arf in the response to chronic, low-dose DNA damage.
The role of p53 in the chronic DNA damage response in p19Arf null cells
The classical role for p19Arf downstream of oncogene activation is stabilization of p53 via inhibition of the negative regulator Mdm2. The same molecular mechanism could underlie the role of p19Arf in the response to chronic, low-dose DNA damage. Alternatively, the chronic DNA damage response could occur through a mechanistically distinct pathway, in which the role for p19Arf is independent of p53. To begin to distinguish these possibilities, we assessed p53 protein stabilization in wild-type and p19Arf−/− MEFs after 4 days of daily 0.5 Gy γ-irradiation treatment, before we observe an arrest response. Interestingly, while basal p53 levels are notably lower in p19Arf−/− MEFs than in wild-type MEFs, as observed previously,18 after 4 days of chronic DNA-damaging agent treatment, p53 levels in p19Arf−/− MEFs approach levels in wild-type MEFs (Figure 3a). These data suggest that the inability of p19Arf−/− MEFs to senesce in response to chronic DNA damage is not due to a complete lack of p53 stabilization. To further probe the p53-dependence of the role of p19Arf in the chronic DNA damage response, we examined the expression of p53 target genes after 4 days of daily 0.5 Gy γ-irradiation treatments. First, we found that wild-type MEFs maintained at 2% O2 displayed increased expression of p53 target genes upon chronic DNA-damaging agent treatment (Figure 3b). Second, and consistent with the observed increase in p53 protein stability upon chronic DNA damage exposure, we also observed increased expression of p21, Mdm2 and Ccng1 in p19Arf-null MEFs treated with chronic damage relative to untreated p19Arf-deficient cells, while these transcripts were not induced in p53-null MEFs (Figure 3b). Taken together, these data demonstrate that the p53 pathway is quite functional in p19Arf-null MEFs subjected to a chronic, low-dose DNA-damaging agent treatment, suggesting that complete disruption of the p19Arf-p53 axis does not underlie the failure to undergo senescence that we observed in p19Arf-null cells. However, the extent of p53 accumulation and p53 target gene activation in p19Arf-null cells is slightly reduced relative to wild-type cells, suggesting that the ability of p19Arf to 'fine-tune' p53 responses and stimulate full p53 induction contributes to the chronic DNA damage response.
We reasoned that if the p19Arf-p53 axis underlies the role of p19Arf in the response to chronic DNA damage, we could activate p53 downstream of p19Arf and promote cell cycle arrest in p19Arf−/− cells. Conversely, if p53 activation in p19Arf−/− cells fails to promote cell cycle arrest in response to chronic damage, then some other p53-independent mechanism must be required for p19Arf function in this context. To distinguish these models, we used the p53 activator Nutlin3a. As an inhibitor of the p53-Mdm2 interaction, Nutlin3a liberates p53 to trigger target gene activation and cell cycle arrest.31 We treated MEFs with 1 μM Nutlin3a, a dose that we found could promote cell cycle arrest or senescence in wild-type MEFs, but only when combined with chronic γ-irradiation, indicating that the arrest depends on the chronic DNA-damaging agent treatment. In contrast, p53-null MEFs did not mount an arrest or senescence response, indicating that this cell cycle arrest response is p53-dependent (Figures 4a and b). Although wild-type MEFs treated with the vehicle control (dimethyl sulfoxide) and subjected to daily 0.5 Gy γ-irradiation treatments underwent a statistically significant arrest and senesced after 10 days of treatment, combination treatment with both 1 μM Nutlin3a and 0.5 Gy γ-irradiation daily triggered a more potent cell cycle arrest in wild-type MEFs. This cell cycle arrest, in contrast to that triggered by daily 0.5 Gy γ-irradiation alone, was statistically significant by day 4, and also promoted senescenceby day 10 (Figure 4a, Supplementary Figure 1). Interestingly, p19Arf-deficient cells did not display appreciable cell cycle arrest or senescence when treated with both 1μM Nutlin3a and daily low-dose irradiation (Figure 4a, Supplementary Figure 1). p53 protein levels were not substantially different between the wild-type and p19Arf−/− samples, suggesting that gross variations in p53 stabilization do not appear to underlie the differences between the observed phenotypes in these two genotypes (Figure 4b).
Collectively, our observations provide genetic evidence that p19Arf is dispensable for the acute DNA damage response but has a critical role in the response to chronic, low-level DNA damage. Notably, we do not observe significant induction of p19Arfupon exposure of cells to chronic DNA damage, either at the mRNA level or at the protein level, as assessed by analysis of p19Arf localization to nucleoli, where it is stable and active32 (Supplementary Figure 2). Therefore, although p19Arf is important for the response to chronic DNA damage, it is not clearly upregulated by such signals. The notion that p19Arf is important for the chronic DNA damage response is supported by other studies. For example, one study reported a partial impairment in the DNA damage response in p19Arf-deficient MEFs.18 Moreover, Arf depletion in Brca2-deficient MEFs or human cells rescued senescence33 and deletion of the Ink4a/Arf locus (both p19Arf and p16Ink4a) rescued premature senescence in cells with a hypomorphic ATR mutation, which induces replication fork collapse and DNA damage.34 In addition, although p19Arf acts at least in part by promoting the efficient activation of p53, our experiments using Nutlin3a in combination with chronic low-dose irradiation suggest the possibility of a p53-independent role for p19Arf in the response to chronic DNA damage (Figure 4c). Numerous activities beyond p53 regulation have been described for p19Arf, including regulating superoxide production,35 ribosomal biogenesis36 and sumoylation of interacting proteins.37 Analysis of such Arf functions in the responses to chronic, low-level DNA damage will be very interesting avenues for future investigation.
Here, we leverage the widely used primary MEF model to better understand the contribution of p19Arf to senescence and tumor suppression in response to chronic, low-dose DNA damage. Evidence for an activated a DNA damage response has been found in developing human tumors, leading to a model in which oncogenic signaling induces DNA replication stress and double-strand breaks, engendering a DNA damage response that triggers p53 activation.20, 21, 25 DNA damage signals are complemented by oncogene-mediated activation of Arf to promote senescence and suppress tumorigenesis, through p53 activation and/or p53-independent functions of Arf.26 Our studies provide additional insight into how incipient tumor cells can activate the p19Arf-p53 suppressor axis as a result of the chronic DNA damage they sustain, illuminating a link between the activated DNA damage response observed in nascent tumors and the functional requirement for p19Arf in tumor suppression. Notably, several studies using mouse models have suggested that the p53 acute DNA damage response is dispensable for tumor suppression,12, 13, 38, 39, 40, 41 a notion seemingly at odds with the presence of activated components of the DNA damage response cascade seen in human tumors. Our results resolve this discrepancy by suggesting that the response to chronic, low-level DNA damage is a p19Arf-dependent mechanism that is distinct from the response to acute DNA damage and may be particularly important for p53-mediated tumor suppression. Continued investigation into the complex interplay between the DNA damage response, Arf, and tumor suppression—an ever-evolving area42, 43—will ultimately help decipher key tumor suppressor pathways.
References
Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997; 91: 649–659.
Sherr CJ, DePinho RA . Cellular senescence: mitotic clock or culture shock? Cell 2000; 102: 407–410.
Campisi J, d'Adda di Fagagna F . Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8: 729–740.
Packer L, Fuehr K . Low oxygen concentration extends the lifespan of cultured human diploid cells. Nature 1977; 267: 423–425.
Chen Q, Fischer A, Reagan JD, Yan LJ, Ames BN . Oxidative DNA damage and senescence of human diploid fibroblast cells. Proc Natl Acad Sci USA 1995; 92: 4337–4341.
Lee AC, Fenster BE, Ito H, Takeda K, Bae NS, Hirai T et al. Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem 1999; 274: 7936–7940.
Parrinello S, Samper E, Krtolica A, Goldstein J, Melov S, Campisi J . Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol 2003; 5: 741–747.
Di Micco R, Cicalese A, Fumagalli M, Dobreva M, Verrecchia A, Pelicci PG et al. DNA damage response activation in mouse embryonic fibroblasts undergoing replicative senescence and following spontaneous immortalization. Cell Cycle 2008; 7: 3601–3606.
Mallette FA, Gaumont-Leclerc MF, Ferbeyre G . The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev 2007; 21: 43–48.
Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006; 444: 638–642.
Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006; 444: 633–637.
Efeyan A, Garcia-Cao I, Herranz D, Velasco-Miguel S, Serrano M . Tumour biology: policing of oncogene activity by p53. Nature 2006; 443: 159.
Christophorou MA, Ringshausen I, Finch AJ, Swigart LB, Evan GI . The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 2006; 443: 214–217.
Kamijo T, van de Kamp E, Chong MJ, Zindy F, Diehl JA, Sherr CJ et al. Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function. Cancer Res 1999; 59: 2464–2469.
Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998; 17: 5001–5014.
Lowe SW, Ruley HE, Jacks T, Housman DE . p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957–967.
Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71: 587–597.
Khan SH, Moritsugu J, Wahl GM . Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion. Proc Natl Acad Sci USA 2000; 97: 3266–3271.
Tanaka S, Diffley JF . Deregulated G1-cyclin expression induces genomic instability by preventing efficient pre-RC formation. Genes Dev 2002; 16: 2639–2649.
Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434: 907–913.
Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434: 864–870.
Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, DePinho RA et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997; 91: 25–34.
Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 2002; 9: 1031–1044.
Chin L, Artandi SE, Shen Q, Tam A, Lee SL, Gottlieb GJ et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999; 97: 527–538.
Halazonetis TD, Gorgoulis VG, Bartek J . An oncogene-induced DNA damage model for cancer development. Science 2008; 319: 1352–1355.
Evangelou K, Bartkova J, Kotsinas A, Pateras IS, Liontos M, Velimezi G et al. The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis. Cell Death Differ 2013; 20: 1485–1497.
Bester AC, Roniger M, Oren YS, Im MM, Sarni D, Chaoat M et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell 2011; 145: 435–446.
Celeste A, Petersen S, Romanienko PJ, Fernandez-Capetillo O, Chen HT, Sedelnikova OA et al. Genomic instability in mice lacking histone H2AX. Science 2002; 296: 922–927.
d'Adda di Fagagna F . Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer 2008; 8: 512–522.
Borel F, Lacroix FB, Margolis RL . Prolonged arrest of mammalian cells at the G1/S boundary results in permanent S phase stasis. J Cell Sci 2002; 115: 2829–2838.
Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844–848.
Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D . Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1999; 1: 20–26.
Carlos AR, Escandell JM, Kotsantis P, Suwaki N, Bouwman P, Badie S et al. ARF triggers senescence in Brca2-deficient cells by altering the spectrum of p53 transcriptional targets. Nat Commun 2013; 4: 2697.
Monasor A, Murga M, Lopez-Contreras AJ, Navas C, Gomez G, Pisano DG et al. INK4a/ARF limits the expansion of cells suffering from replication stress. Cell Cycle 2013; 12: 1948–1954.
Christensen C, Bartkova J, Mistrik M, Hall A, Lange MK, Ralfkiaer U et al. A short acidic motif in ARF guards against mitochondrial dysfunction and melanoma susceptibility. Nat Commun 2014; 5: 5348.
Lessard F, Morin F, Ivanchuk S, Langlois F, Stefanovsky V, Rutka J et al. The ARF tumor suppressor controls ribosome biogenesis by regulating the RNA polymerase I transcription factor TTF-I. Mol Cell 2010; 38: 539–550.
Kuo ML, den Besten W, Thomas MC, Sherr CJ . Arf-induced turnover of the nucleolar nucleophosmin-associated SUMO-2/3 protease Senp3. Cell Cycle 2008; 7: 3378–3387.
Hinkal G, Parikh N, Donehower LA . Timed somatic deletion of p53 in mice reveals age-associated differences in tumor progression. PLoS One 2009; 4: e6654.
Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 2011; 145: 571–583.
Valente LJ, Gray DH, Michalak EM, Pinon-Hofbauer J, Egle A, Scott CL et al. p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effect p21, Puma, and Noxa. Cell Rep 2013; 3: 1339–1345.
Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012; 149: 1269–1283.
Kotsinas A, Papanagnou P, Galanos P, Schramek D, Townsend P, Penninger JM et al. MKK7 and ARF: new players in the DNA damage response scenery. Cell Cycle 2014; 13: 1227–1236.
Velimezi G, Liontos M, Vougas K, Roumeliotis T, Bartkova J, Sideridou M et al. Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer. Nat Cell Biol 2013; 15: 967–977.
Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92: 9363–9367.
Acknowledgements
We thank Dr Charles Sherr for the kind gift of the p19Arf antibody and Nitin Raj and Margot Bowen for critical reading of the manuscript. KBR was funded by an American Cancer Society postdoctoral fellowship 122767-PF-12-195-01-TBG. This work was supported by funding from the American Cancer Society (RSG-06-065-01-MGO), the Leukemia and Lymphoma Society (LLS-1012-09), and the National Institutes of Health (CA140875) to LDA.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Bieging-Rolett, K., Johnson, T., Brady, C. et al. p19Arf is required for the cellular response to chronic DNA damage. Oncogene 35, 4414–4421 (2016). https://doi.org/10.1038/onc.2015.490
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2015.490
- Springer Nature Limited
This article is cited by
-
Deconstructing networks of p53-mediated tumor suppression in vivo
Cell Death & Differentiation (2018)
-
p53 loss does not permit escape from BrafV600E-induced senescence in a mouse model of lung cancer
Oncogene (2017)
-
Nucleolus-derived mediators in oncogenic stress response and activation of p53-dependent pathways
Histochemistry and Cell Biology (2016)